- Record: found
- Abstract: not found
- Article: not found
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
Sagar Lonial ,
Hans C Lee ,
Ashraf Badros ,
Suzanne Trudel ,
Ajay K Nooka ,
Ajai Chari ,
Al-Ola Abdallah ,
Natalie Callander ,
Nikoletta Lendvai ,
Douglas Sborov ,
Attaya Suvannasankha ,
Katja Weisel ,
Lionel Karlin ,
Edward Libby ,
Bertrand Arnulf ,
Thierry Facon ,
Cyrille Hulin ,
K Martin Kortüm ,
Paula Rodríguez-Otero ,
Saad Z Usmani ,
Parameswaran Hari ,
Rachid Baz ,
Hang Quach ,
Philippe Moreau ,
Peter M Voorhees ,
Ira Gupta ,
Axel Hoos ,
Eric Zhi ,
January Baron ,
Trisha Piontek ,
Eric Lewis ,
Roxanne C Jewell ,
Elisha J Dettman ,
Rakesh Popat ,
Simona Degli Esposti ,
Joanna Opalinska ,
Paul Richardson ,
Adam D Cohen
December 2019
December 2019
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Belantamab mafodotin (GSK2857916), an immunoconjugate targeting B-cell maturation
antigen, showed single-agent activity in the phase 1 DREAMM-1 study in heavily pre-treated
patients with relapsed or refractory multiple myeloma. We further investigated the
safety and activity of belantamab mafodotin in the DREAMM-2 study.